Document is current
Any future updates will be listed below
-
Authors
Borilova, Simona
Grell, Peter
Selingerova, Iveta
Gescheidtova, Lenka
Mlnarikova, Marie
Bilek, Ondrej
Lakomy, Radek
Poprach, Alexandr
Podhorec, Jan
Kiss, Igor
Vyzula, Rostislav
Vavrusakova, Barbora
Nevrlka, Jiri
Zdrazilova-Dubska, Lenka
-
Funding
Funding for this research was provided by:
Development of Research Organization MMCI (00209805)
National Institute for Cancer Research (LX22NPO5102)
Ministry of Health of the Czech Republic (NU21-03-00539)
European Union—Next Generation EU and by Specific University Research (MUNI/A/1580/2023)
- License Information
-
More Information
Article History
Received: 17 July 2024
Accepted: 16 December 2024
First Online: 30 December 2024
Declarations
:
: The study was conducted in accordance with the Declaration of Helsinki, and approved by the Institutional Review Board and Ethics Committee of Masaryk Memorial Cancer Institute, reference number 2017/1890/MOU; 27 June 2017.
: Informed consent was obtained from all individual participants included in the study.
: Not applicable.
: Dr. Borilova reported receiving personal fees from Bristol Myers Squibb and MSD outside the submitted work, Dr. Grell reported receiving personal fees from Bristol Myers Squibb, Roche and Servier outside the submitted work, Dr. Poprach reported receiving personal fees from Roche, Bristol Myers Squibb, Merck KGaA, MSD, Novartis, Astellas, Janssen, and Sanofi/Aventis, Ipsen, and Pfizer outside the submitted work. The other authors have no competing interests to declare that are relevant to the content of this article.
